Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 18

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 Shares   Weighted- average Exercise Price   Weighted- average Remaining Contractual Term (years)   Aggregate Intrinsic Value   Outstanding at January 1, 2025   7,203,307   $8.29    6.49   $1,218   Options granted   100,000   $7.88    10.0    -   Options exercised   -   $-    -    -   Options cancelled   -   $-    -    -   Outstanding at March 31, 2025   7,303,307   $8.28    6.29   $9,372   Exercisable at March 31, 2025   5,124,039   $8.71    5.01   $6,248  

During the three months ended March 31, 2025 and
2024, the Company recognized stock-based compensation expense of approximately $2.1 million and $1.8 million, respectively, related to
the vesting of stock options. As of March 31, 2025, there was approximately $10.8 million of total unrecognized compensation cost related
to non-vested stock options which is expected to be recognized over a weighted-average period of 2.59 years.

14

Warrants

The Company issued warrants to the Company’s
lenders upon obtaining a loan in June 2021. The warrants have a 10-year term and an exercise price of $14.05. At March 31, 2025,
respectively, 45,386 of these warrants are outstanding and the intrinsic value of these warrants is $0.

During April
2024, the Company issued 1,557,592 warrants to investors in connection with the sale of common stock. At March 31, 2025, 1,557,592 of
these warrants are outstanding and are exercisable for cash at a weighted average price of $9.59 per share. The intrinsic value of
these warrants was $0 as of March 31, 2025.

During September
2024, the Company issued 2,341,260 warrants to investors in connection with the sale of common stock. At March 31, 2025, 2,341,160